Similar articles

• Thalidomide in multiple myeloma: state of art.

  Tosi P, Cavo M. Tosi P, et al. Haematologica. 2002 Mar;87(3):233-4. Haematologica. 2002. PMID: 11869932 No abstract available.
• Thalidomide-induced neuropathy.

  Crawford CL. Crawford CL. Mayo Clin Proc. 2002 Dec;77(12):1395; author reply 1395. doi: 10.4065/77.12.1395. Mayo Clin Proc. 2002. PMID: 12479531 No abstract available.
• Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma.

  Trojan A, Chasse E, Gay B, Pichert G, Taverna C. Trojan A, et al. Ann Oncol. 2003 Mar;14(3):501-2. doi: 10.1093/annonc/mdg095. Ann Oncol. 2003. PMID: 12598363 No abstract available.
• [Treatment of myeloma when high dose therapy is not possible. New drugs--alternatives for elderly patients].

  Mellstedt H, Gimsing P, Waage A. Mellstedt H, et al. Lakartidningen. 2011 Oct 19-25;108(42):2090-4. Lakartidningen. 2011. PMID: 22165535 Review. Swedish. No abstract available.
• Immunomodulatory drugs.

  Crane E, List A. Crane E, et al. Cancer Invest. 2005;23(7):625-34. doi: 10.1080/07357900500283101. Cancer Invest. 2005. PMID: 16305990 Review.